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INTRODUCTION 
Oral mucositis (OM) is a common complication 
in patients subjected to chemotherapy (CT) and/or 
radiotherapy (RT), affecting approximately 80% of 
patients undergoing RT for treatment of tumors of 
the head and neck (1). Its occurrence is associated 
with severe pain, dysphasia, and increased risk of 
oral infection by opportunistic pathogens. OM has a 
great impact on patients’ quality of life, increasing 
the morbidity and mortality, and adding a significant 
economic cost (2-4). 
Prevention and treatment of OM have been 
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mainly empirical and widely affected by basic oral care, 
analgesics, antibiotics and local anesthetics, yonder 
cryotherapy, growth factors, cytokines, biological 
mucosal protectants, antiinflammatory agents and 
complementary and alternative medicines (3). 
Mucosal protective drugs, such as sucralfate, a 
complex salt of sucrose sulfate and aluminum hydroxide 
(AH), have been used for the treatment of OM (5). They 
provide a protective coating due to an ionic adhesion 
affinity with proteins of the damaged mucosa and 
provide local production of prostaglandin, increasing the 
blood flow and mitotic activity, as well as the surface 
migration of cells (6). 
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The use of sucralfate is considered a viable option 
due to the low cost, easy administration and absence of 
adverse effects. However, reports in the literature are 
conflicting (6-8).  
Double-blind, randomized, prospective studies 
(6-8) have evaluated patients subjected to RT in the 
region of the head and neck in which the study group 
was treated with sucralfate and the control group received 
placebo. Carter et al. (6) observed OM grade III in 50% 
of the control patients and 43% of the patients in the 
study group (p=0.31), while significant reduction of 
OM after sucralfate use was found by Cengiz et al. (7) 
(p<0.05) and Etiz et al. (8) (p=0.0002). 
Low-level laser therapy (LLLT) or prophylactic 
laser irradiation provides mainly the acceleration of 
wound healing. However, the major clinical indication of 
LLLT has historically been analgesia (9). LLLT produces 
wound healing by the transformation of fibroblasts 
into myofibroblasts, which are responsible for wound 
contraction (9,10).
The use of LLLT has been associated with the 
treatment of CT-induced OM (10-14), but few studies 
have been carried out with patients with OM lesions 
induced by RT (2,15,16). 
The prophylactic effects of LLLT were first 
presented in a non-randomized retrospective study 
published in the early 1990’s (10). Sixty-seven patients 
with cancer of different origins and locations were 
subjected to CT. The sample was divided into 3 groups: 
a control group and two other groups that received 
curative and prophylactic laser. The group treated with 
LLLT presented lower incidence of OM and was the only 
group in which the protocol did not have to be modified.
Barasch et al. (11) and Cowen et al. (12) 
conducted double-blind and randomized studies in 
patients undergoing bone marrow transplant. In both 
studies, the patients were divided into 2 groups: the 
study group received LLLT to evaluate its effect on 
the prevention of OM and the control group received 
placebo. Barasch et al. (11) found significant better 
results with the use of LLLT for pain reduction (p=0.027) 
and for evaluation of OM index (p<0.005). Although 
no statistically significant difference was found in the 
evaluation of the oral toxicity scale (OTS), Cowen et 
al. (12) observed a reduction in OM severity (p=0.01) 
and pain (p=0.05) in the laser-treated group. 
Bensadoun et al. (2) were the first to carry out a 
double-blind and randomized study to evaluate effects 
of prophylactic laser only in patients with RT-induced 
OM. Thirty patients with head and neck cancer were 
treated with either LLLT or placebo. The frequency of 
OM grade III was 7.6% in the LLLT group and 35.2% 
in the placebo group. Severe pain occurred in 1.9% of 
the patients in LLLT group and 23.8% of those in the 
placebo group (p<0.05). The authors concluded that the 
laser is a safe and efficient method for the prevention 
of RT-induced OM. 
A prospective and controlled study has been 
developed to evaluate the efficacy of LLLT on the 
prevention and treatment of RT-induced OM (16). 
Twenty-four patients with oral cancer were allocated 
to a group treated with laser or a group that served as a 
control. The LLLT group presented significantly better 
results in both pain and OM evaluations at the 2nd week 
(p=0.004), 3rd week (p=0.000), 4th week (p=0.029), 
5th week (p=0.031), 6th week (p=0.019) and 7th week 
(p=0.045).
Although the literature presents effective results 
of LLLT in the reduction of OM severity, the scarcity of 
studies with patients subjected to RT in the region of the 
head and neck, and the morbidity of the treatment have 
stimulated the development of the present investigation. 
There are still many aspects to be clarified about laser 
therapy: the mechanism of action, the best application 
mode, the ideal wavelength, and the amount of released 
energy, among other questions. Regarding AH, the 
therapeutic role of this drug in OM treatment and the 
practicality of its use have motivated its inclusion in the 
study methodology.
The present study evaluated the capacity of 
LLLT and prophylactic AH in preventing or delaying 
the appearance of CT- and RT-induced OM, and the 
pain deriving from the lesions. The impact of OM on 
the ability to swallow and the patients’ life quality were 
evaluated. 
MATERIAL AND METHODS
The study was conducted between July and 
December 2005 in patients with diagnosis of head and 
neck tumors treated with RT associated or not with 
CT at the Radiotherapy and Oncology Division of 
the Institute of Radiology and Dentistry Division of 
the Clinics Hospital’s Central Institute at the Medical 
School, University of São Paulo, Brazil. All patients 
were subjected to dental treatment before the oncology 
therapy to remove focus of infections, and received oral 
hygiene instructions. 
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Study Design
A prospective, comparative and non-randomized 
study was conducted with 25 patients after approval 
of the research protocol by the local Research Ethics 
Committee. The sample was divided into 2 groups: 
Group I was subjected to LLLT and Group II received 
AH suspension. 
Inclusion Criteria
To be considered as eligible for this study, the 
patients had to present all the following characteristics: 
tumor in the head and neck region; ongoing treatment 
by external RT with a total dose ranging from 4,000 to 
7,000 cGy at a rate of 1 fraction of 1, 8 to 2 Gy/day, 5 
days a week (Monday to Friday), from linear accelerator 
(photons and electrons); age ranging from 18 to 80 years 
in an attempt to evaluate all adult patients with KPS>70 
treated in the Radiotherapy Division; written informed 
consent for participation in the study.
Treatments
Group I: Twelve patients were subjected to LLLT 
applications by a diode (Laser Unit KM 3000; DMC, São 
Carlos, SP, Brazil) with wavelength 830 nm, nominal 
power 60 mW, effective power 15 mW and 0.2 cm2 
aperture. The laser was delivered in a punctual form and 
the energy released by point was 2.4 J, giving an energy 
density of 12 J/cm2. Patients had laser applications daily 
since the first day of RT up to the end of the therapy 
during 5 consecutive days (Monday to Friday), before 
RT sessions. The laser was applied in 12 areas of the 
oral cavity, including the region of the upper and the 
lower labial mucosa, soft palate, buccal mucosa, lateral 
region of the tongue and floor of the mouth bilaterally. 
Laser was applied in the areas considered to the most 
susceptible for the occurrence of OM, that is, non-
keratinized mucosas. The tumor areas were avoided and 
the patients wore specific protective glasses during the 
laser sessions to prevent eye injuries. 
Group II: Thirteen patients received the AH 
suspension (310 mg/5 mL) since the first day of RT up 
to the end of the therapy, including weekends. Patients 
were instructed to use 10 mL of the mouthwash 4 times 
daily, and then to swallow the suspension. They were 
told to avoid eating during the first hour after treatment. 
The association of RT and CT was allowed since 
the CT was to be performed with cisplatin, a drug that 
presents low potential for stomatotoxicity. In such case, 
the risk of occurrence of OM would be similar in both 
treatments. The use of concomitant antiinflammatory 
and/or analgesic was also allowed in both groups. 
Nistatin was prescribed in case there was any sign of 
fungal infection.
The National Cancer Institute’s (NCI) oral 
toxicity scale (OTS) was used for OM evaluation and 
the visual analogue scale (VAS) was used for pain 
evaluation. The VAS was modified according to the 
scale proposed by Bensadoun et al. (2): scores 1 and 
2 (mild pain) were considered grade I, scores 3 and 4 
(moderate pain) were grade II, scores of 5 to 7 (severe 
pain) were grade III and scores of 8 to 10 (very severe 
pain) were grade IV. The evaluations were performed 
twice a week during the entire RT period. 
Quality of life was evaluated by two questionnaires 
developed by the European Organization for Research 
and Treatment of Cancer (EORTC), an international 
non-profit organization that develops, coordinates and 
stimulates cancer laboratory and clinical research in 
Europe (17). The questionnaires QLQ-C30 and QLQ-
H&N35 were applied at the beginning and end of RT. 
Outcomes
Data referring to OM severe grades as defined by 
the NCI, time of appearance of severe OM, severe pain 
according to the VAS, swallowing capacity according to 
the NCI and quality of life according to the EORTC’s 
questionnaires, were analyzed statistically by the Mann-
Whitney and Wilcoxon tests (α=0.05).
RESULTS
Three patients were excluded from the sample: 
two patients missed the clinical appointments for oral 
examination and one patient died. All excluded patients 
belonged to the AH group. The sample of this study was 
composed by 22 patients, 20 men (90.91%) and 2 women 
(9.08%), with ages ranging from 33 to 80 years (mean 
age = 55.82 years). Squamous cell carcinoma was the 
most common type of tumor, corresponding to 77.27% of 
the sample. The most frequent location was the region of 
the oropharynx, corresponding to 40.91% of the patients. 
Nineteen patients could be classified according to the 
TNM clinical staging system; 89.47% of these patients 
were classified as stage IV and 10.53% as stage III. 
Braz Dent J 21(3) 2010
Laser and aluminum hydroxide in oral mucositis 189
The RCT was the choice of treatment for 81.82% 
of the sample (18 patients) and the other patients were 
subjected to RT only. The daily radiation dose was 200 
cGy in 86.36% of the sample (19 patients). The total 
dose was over 6000 cGy in 90.91% (20 patients). The 
areas more frequently involved in the irradiation field 
between the areas evaluated in the study were: the soft 
palate, the buccal mucosa, the lateral surface of tongue 
and the floor of the mouth (Tables 1 and 2). 
Clinical Evaluation
According to the OTS, lower mean OM scores 
were observed in the LLLT group throughout the duration 
of the RT period, with values near to the significance 
level (p=0.061) between the 18th and 20th RT sessions 
(Fig. 1). During the RT treatment, grade IV OM was 
not observed. OM grade III occurred in 33.33% of the 
patients in the LLLT group compared to 50% in the AH 
group. The LLLT group (Fig. 2A) presented severe OM 
only after the 5th week of RT, while in the AH group 
severe OM occurred in the 2nd treatment week (Fig. 2B).
Functional Evaluation
The LLLT group also presented lower scores 
during the RT treatment (Fig. 3), though without 
statistical significance. Severe grades (III and IV) of 
dysphagia were found in approximately 33% of the 
LLLT group versus 50% of the AH group.
Pain Evaluation
Lower mean pain scores were observed in the 
laser group during the whole RT treatment, except in 
the 33rd RT session. A statistically significant difference 
was observed only in the 13th RT session, in which the 
LLLT group presented important mean pain reduction 
compared to the AH group (p=0.036) (Fig. 4). During 
the whole RT treatment, very severe pain (grade IV) 
was reported by only 1 patient of the AH group, while 
3 other patients of the same group and 1 patient of the 
LLLT group presented severe pain (grade III).
Quality of Life Evaluation
The analysis of the EORTC’s quality of life 
questionnaires showed a marked worsening in the final 
evaluation compared to the initial evaluation in almost 
all questions asked during RT in both groups. The main 
mean scores of questions evaluated in this study can be 
seen in Table 3, keeping in mind that a high score for a 
symptom indicates a high level of symptomatology (17).
The questions about dry mouth, sticky saliva and 
pain killers presented worse index in the final evaluation 
compared to the initial index for both groups. However, 
the LLLT group presented better scores compared 
to the AH group in all these questions cited above, 
though without statistical significance. In the same way, 
the questions involving coughing, sense and speech 
problems presented a worse index in the final evaluation 
for both groups, except for the AH group that presented 
the same score in the question about coughing in both 
evaluations. In addition, the AH group presented better 
scores for these questions compared to the LLLT group, 
with statistically significant difference in the speech 
problems item (p=0.05). 
At the end of the treatment, none of the patients 
of either of the groups needed to suspend the RT or RCT, 
due to the severity of the OM. 
DISCUSSION
The best approach to treat advanced head and 
neck tumors is the association of treatments: surgery plus 
Table 1. Primary tumor location in patients from the study 
according to each group.
Primary tumor 
location
Low-level 
laser therapy
Aluminum 
hydroxide
Rhinopharynx 1 0
Larynx 2 0
Hypopharynx 2 1
Oral cavity 1 3
Oropharynx 5 4
Others 1 2
Table 2. Total and daily doses given to the patients of each  group.
Total dose LLLT AH Daily dose LLLT AH
40-59 Gy 1 1 180 cGy 3 0
60-70 Gy 11 9 200 cGy 9 10
LLLT = low-level laser therapy; AH = aluminum hydroxide.
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RCT or RCT. However, the combination of treatments in 
general is also associated with morbidity. A worsening 
in the quality of life questions scores was observed in 
the questionnaires for RCT therapy in the present study, 
which shows its high toxicity and the importance of 
using treatments to decrease side-effects. 
Previous studies (2,15,16) performed in patients 
treated only with RT found good results with the use 
of LLLT in the prevention of OM. In the present study, 
which was performed with most patients receiving RCT, 
the prophylactic use of both treatments, compared to 
historical controls, apparently reduced the incidence 
of severe OM. This meant no interruption of RT, which 
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Figure 1. Mean scores of OM (clinical evaluation) by OTS 
according to the number of RT sessions.
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Figure 3. Mean scores of swallowing capacity by OTS according 
to the number of RT sessions.
Figure 4. Mean scores of pain by VAS according to the number 
of RT sessions.
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Figure 2. Onset of the appearance of oral mucositis through the 
OTS according to the RT weeks in the LLLT (A) and aluminum 
hydroxide (B) groups.
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clearly has a positive impact on treatment outcome. 
According to Buffa et al. (18), for each day of treatment 
suspended, a reduction of nearly 1% in survival for the 
patient is expected. 
The mechanisms of action of laser are not 
completely known. Attenuating pain, stimulating 
endorphin release and modulating the immune system 
are some of the effects caused by LLLT. LLLT can 
also influence the wound healing process by   the 
transformation of fibroblasts into myofibroblasts, 
which are responsible for wound contraction (19,20). In 
addition, the use of prophylactic laser seems to be more 
efficient than the AH prophylactic use (12).
To date, a great variety of doses ranging from 0.75 
J/cm2 (10) to 35 J/cm2 (13) have been evaluated for the 
prophylactic and curative treatment of OM. Before the 
beginning of the present study, the laser was calibrated 
at the University of São Paulo’s Technological Research 
Institute, obtaining an effective power of 15 mW. As we 
used to apply the laser during 40 s, a 160-s-irradition 
time was used to try to recover the effect lost with 
power reduction, resulting in an energy density of 12 
J/cm2. The use of a high energy density did not cause 
adverse effects.
Although the visible red laser has been more 
frequently used for the healing of OM lesions, an 
infrared laser was used in this study because we have 
experience with the use of this laser in the treatment 
of OM with the above-mentioned dose. Satisfactory 
results  were obtained in the reduction of OM and pain 
in non-prophylactic treatments. The decision to use daily 
LLLT was based on the study by Bensadoun et al. (2), 
who used LLLT in patients with OM lesions induced 
by RT and presented beneficial results with the daily 
application of LLLT.
In the present study, signs of OM were seen only 
between the 2nd and 3rd weeks in the LLLT group (peak 
in the 6th week). The present results showed that the use 
of LLLT was also effective to delay the appearance of 
the severe OM lesions, in the same way as reported by 
previous studies comparing LLLT and control groups of 
patients (2,15,16). In the present investigation, the lower 
incidence of severe OM in the LLLT group compared to 
the AH group was not highly evident probably because 
a placebo group was not included. 
The powerful analgesic effect of LLLT has been 
reported. It has been demonstrated that low-power lasers 
can promote a decrease in the frequency of nociceptors 
and an increase in endorphin synthesis (9).
The AH group also showed a decrease in OM and 
no patient of this group had the RT or RCT treatment 
suspended. According to the EORTC questionnaire, AH 
presented higher efficacy than laser in coughing control, 
speech problems, sense problems and trouble with social 
contact (Table 2). This is probably because it is an oral 
suspension that can be swallowed, entering in contact 
not only with the oropharynx and the oral mucosa, but 
also with the esophagus. 
Although the literature is controversial about 
the use of sucralfate, there is evidence that this drug 
can promote mucus production and local production of 
prostaglandin, thus increasing blood flow. Additionally, 
sucralfate can increase the mitotic activity and surface 
migration of cells, and provide binding of epithelial 
growth factors and basic fibroblastic growth factors 
to tissues (5). In our estimation, this fact justifies the 
prophylactic use of the drug in the absence of other 
resources. Moreover, some authors have recommended 
the use of sucralfate (7,8), a drug that contains AH, 
mainly because it is a low-cost drug, with easy 
administration and no adverse effects. 
The association of two prophylactic 
measures can probably produce more 
satisfactory results.
However, several questions 
should be clarified about the use of 
laser, regarding not only the ideal 
frequency and wavelength, but also the 
best description of its mechanism of 
action, which will certainly contribute 
to a more widespread the indication  of 
this therapeutic resource. 
In conclusion, the prophylactic 
use of both treatments proposed in 
Table 3. Mean scores obtained in the EORTC’s quality of life questionnaires for 
both groups.
Questions
Low-level laser therapy Aluminum hydroxide
Initial mean Final mean Initial mean Final mean
Dry mouth 13.80 52.75 20.0 56.7
Sticky saliva 16.66 63.83 50.0 86.70
Pain killers 41.66 50.0 60.0 80.0
Coughing 33.25 47.16 30.0 30.0
Sense problems 19.41 41.66 13.30 36.70
Speech problems 52.25 67.75 24.40 44.40
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this study seems to reduce the incidence of severe OM 
lesions, but LLLT was more effective in delaying their 
appearance. The results obtained with laser radiation in 
the present study have motivated us to keep on studying 
its application in our outpatient clinic. Randomized 
studies to assess mainly RCT-induced OM lesions must 
be developed because reports in the literature for this 
therapeutic modality are scarce.
RESUMO
Este estudo avaliou a eficácia da terapia do laser de baixa potência 
(LBP) e hidróxido de alumínio (HA) na prevenção da mucosite oral 
(MO). Um estudo prospectivo, comparativo e não-aleatorizado 
foi conduzido com 25 pacientes com câncer de cabeça e pescoço 
submetidos a radioterapia (RT) ou radioquimioterapia (RT/QT). 
Doze pacientes receberam LBP (830 nm, 15 mW, 12 J/cm2) 
diariamente desde o primeiro dia até o final da RT antes de cada 
sessão durante 5 dias consecutivos, e os outros 13 pacientes 
receberam HA 310 mg/5 mL, 4 vezes ao dia, também por toda a 
duração da RT, incluindo finais de semana. MO foi mensurada 
usando uma escala de toxicidade oral (ETO) e dor foi mensurada 
usando a escala visual analógica (EVA). Questionários da EORTC 
foram administrados para a avaliação do impacto da MO na 
qualidade de vida. O grupo LBP mostrou menores médias dos 
escores da ETO e EVA durante o curso da RT. Uma diferença 
significante foi observada na avaliação da dor na 13ª sessão de 
RT (p=0,036). Em ambos os grupos, nenhuma interrupção da 
RT foi necessária. O uso profilático de ambos os tratamentos 
propostos neste estudo parece reduzir a incidência de lesões 
severas de MO. No entanto, o LBP foi mais efetivo no atraso do 
aparecimento da MO severa. 
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